title: Management of the thalassemias.
abstract: During the last 30 years, in addition to the considerable progress made in control and prevention of thalassemias(3), there have also been major advances in their symptomatic management, at least in wealthier countries where appropriate facilities are available. Remarkable improvements in survival in the severe forms of thalassemia have followed the more judicious use of blood transfusion and, in particular, the ability to manage the iron accumulation resulting from transfusion with its severe and ultimately lethal effects on endocrine and cardiac function.
authors.affiliation: Hemoglobinopathy Research University Health Network, Toronto, Ontario M5G 2C4, Canada.
authors.forename: Nancy F
authors.initials: NF
authors.lastname: Olivieri
authors.forename: Gary M
authors.initials: GM
authors.lastname: Brittenham
mesh_terms: D001565:Benzoates / Q000191:economics / Q000627:therapeutic use; D001803:Blood Transfusion; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000191:economics / Q000627:therapeutic use; D005293:Ferritins / Q000097:blood; D006801:Humans; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000191:economics / Q000627:therapeutic use; D019190:Iron Overload / Q000628:therapy; D008099:Liver / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D010179:Pancreas / Q000378:metabolism; D010903:Pituitary Gland, Anterior / Q000378:metabolism; D011728:Pyridones / Q000191:economics / Q000627:therapeutic use; D013789:Thalassemia / Q000628:therapy*; D014230:Triazoles / Q000191:economics / Q000627:therapeutic use
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine; D000077588:Deferasirox